

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth (Status and Outlook) 2024-2030

<https://marketpublishers.com/r/G19253D4D500EN.html>

Date: February 2024

Pages: 111

Price: US\$ 3,660.00 (Single User License)

ID: G19253D4D500EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to our LPI (LP Information) latest study, the global B-Cell Maturation Antigen (BCMA) Targeted Therapies market size was valued at US\$ million in 2023. With growing demand in downstream market, the B-Cell Maturation Antigen (BCMA) Targeted Therapies is forecast to a readjusted size of US\$ million by 2030 with a CAGR of % during review period.

The research report highlights the growth potential of the global B-Cell Maturation Antigen (BCMA) Targeted Therapies market. B-Cell Maturation Antigen (BCMA) Targeted Therapies are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of B-Cell Maturation Antigen (BCMA) Targeted Therapies. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the B-Cell Maturation Antigen (BCMA) Targeted Therapies market.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for

development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Key Features:

The report on B-Cell Maturation Antigen (BCMA) Targeted Therapies market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the B-Cell Maturation Antigen (BCMA) Targeted Therapies market. It may include historical data, market segmentation by Type (e.g., Bispecific Antibodies, Antibody Drug Conjugates), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the B-Cell Maturation Antigen (BCMA) Targeted Therapies market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the B-Cell Maturation Antigen (BCMA) Targeted Therapies market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the B-Cell Maturation Antigen (BCMA) Targeted Therapies industry. This include advancements in B-Cell Maturation Antigen (BCMA) Targeted Therapies technology, B-Cell Maturation Antigen (BCMA) Targeted Therapies new entrants, B-Cell Maturation Antigen (BCMA) Targeted Therapies new investment, and other innovations that are shaping the future of B-Cell Maturation Antigen (BCMA) Targeted Therapies.

Downstream Procumbent Preference: The report can shed light on customer

procumbent behaviour and adoption trends in the B-Cell Maturation Antigen (BCMA) Targeted Therapies market. It includes factors influencing customer ' purchasing decisions, preferences for B-Cell Maturation Antigen (BCMA) Targeted Therapies product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the B-Cell Maturation Antigen (BCMA) Targeted Therapies market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting B-Cell Maturation Antigen (BCMA) Targeted Therapies market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the B-Cell Maturation Antigen (BCMA) Targeted Therapies market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the B-Cell Maturation Antigen (BCMA) Targeted Therapies industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the B-Cell Maturation Antigen (BCMA) Targeted Therapies market.

Market Segmentation:

B-Cell Maturation Antigen (BCMA) Targeted Therapies market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Segmentation by type

Bispecific Antibodies

Antibody Drug Conjugates

Chimeric Antigen Receptor T-Cells

Segmentation by application

Liver Cancer

Respiratory Cancer

Brain Cancer

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Transposagen Biopharmaceuticals

Sutro Biopharma

Malin Corporation

Eureka Therapeutics

firstVentury Equity

Five Prime Therapeutics

Credit Suisse Securities

Dana-Farber Cancer Institute

Deerfield Partners

Onyx Pharmaceuticals

Juno Therapeutics

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2019-2030
 - 2.1.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size CAGR by Region 2019 VS 2023 VS 2030
- 2.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Segment by Type
 - 2.2.1 Bispecific Antibodies
 - 2.2.2 Antibody Drug Conjugates
 - 2.2.3 Chimeric Antigen Receptor T-Cells
- 2.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type
 - 2.3.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size CAGR by Type (2019 VS 2023 VS 2030)
 - 2.3.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Type (2019-2024)
- 2.4 B-Cell Maturation Antigen (BCMA) Targeted Therapies Segment by Application
 - 2.4.1 Liver Cancer
 - 2.4.2 Respiratory Cancer
 - 2.4.3 Brain Cancer
 - 2.4.4 Others
- 2.5 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application
 - 2.5.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size CAGR by Application (2019 VS 2023 VS 2030)
 - 2.5.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Application (2019-2024)

3 B-CELL MATURATION ANTIGEN (BCMA) TARGETED THERAPIES MARKET SIZE BY PLAYER

3.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Players

3.1.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Players (2019-2024)

3.1.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Players (2019-2024)

3.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 B-CELL MATURATION ANTIGEN (BCMA) TARGETED THERAPIES BY REGIONS

4.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Regions (2019-2024)

4.2 Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth (2019-2024)

4.3 APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth (2019-2024)

4.4 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth (2019-2024)

4.5 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth (2019-2024)

5 AMERICAS

5.1 Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024)

5.2 Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2019-2024)

5.3 Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2019-2024)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2019-2024)

6.2 APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2019-2024)

6.3 APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2019-2024)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies by Country (2019-2024)

7.2 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2019-2024)

7.3 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2019-2024)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies by Region (2019-2024)

8.2 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

Size by Type (2019-2024)

8.3 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

Size by Application (2019-2024)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 GLOBAL B-CELL MATURATION ANTIGEN (BCMA) TARGETED THERAPIES MARKET FORECAST

10.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast by Regions (2025-2030)

10.1.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast by Regions (2025-2030)

10.1.2 Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast

10.1.3 APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast

10.1.4 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast

10.1.5 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast

10.2 Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast by Country (2025-2030)

10.2.1 United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast

10.2.2 Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast

10.2.3 Mexico B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast

10.2.4 Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast

10.3 APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast by Region (2025-2030)

10.3.1 China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast

10.3.2 Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast

- 10.3.3 Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast
- 10.3.4 Southeast Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast
- 10.3.5 India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast
- 10.3.6 Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast
- 10.4 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast by Country (2025-2030)
 - 10.4.1 Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast
 - 10.4.2 France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast
 - 10.4.3 UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast
 - 10.4.4 Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast
 - 10.4.5 Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast
- 10.5 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast by Region (2025-2030)
 - 10.5.1 Egypt B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast
 - 10.5.2 South Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast
 - 10.5.3 Israel B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast
 - 10.5.4 Turkey B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast
 - 10.5.5 GCC Countries B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast
- 10.6 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast by Type (2025-2030)
- 10.7 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast by Application (2025-2030)

11 KEY PLAYERS ANALYSIS

- 11.1 Transposagen Biopharmaceuticals
 - 11.1.1 Transposagen Biopharmaceuticals Company Information
 - 11.1.2 Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered
 - 11.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
 - 11.1.4 Transposagen Biopharmaceuticals Main Business Overview
 - 11.1.5 Transposagen Biopharmaceuticals Latest Developments
- 11.2 Sutro Biopharma

- 11.2.1 Sutro Biopharma Company Information
- 11.2.2 Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies
Product Offered
- 11.2.3 Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies
Revenue, Gross Margin and Market Share (2019-2024)
- 11.2.4 Sutro Biopharma Main Business Overview
- 11.2.5 Sutro Biopharma Latest Developments
- 11.3 Malin Corporation
- 11.3.1 Malin Corporation Company Information
- 11.3.2 Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies
Product Offered
- 11.3.3 Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies
Revenue, Gross Margin and Market Share (2019-2024)
- 11.3.4 Malin Corporation Main Business Overview
- 11.3.5 Malin Corporation Latest Developments
- 11.4 Eureka Therapeutics
- 11.4.1 Eureka Therapeutics Company Information
- 11.4.2 Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies
Product Offered
- 11.4.3 Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies
Revenue, Gross Margin and Market Share (2019-2024)
- 11.4.4 Eureka Therapeutics Main Business Overview
- 11.4.5 Eureka Therapeutics Latest Developments
- 11.5 firstVentury Equity
- 11.5.1 firstVentury Equity Company Information
- 11.5.2 firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies
Product Offered
- 11.5.3 firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies
Revenue, Gross Margin and Market Share (2019-2024)
- 11.5.4 firstVentury Equity Main Business Overview
- 11.5.5 firstVentury Equity Latest Developments
- 11.6 Five Prime Therapeutics
- 11.6.1 Five Prime Therapeutics Company Information
- 11.6.2 Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies
Product Offered
- 11.6.3 Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies
Revenue, Gross Margin and Market Share (2019-2024)
- 11.6.4 Five Prime Therapeutics Main Business Overview
- 11.6.5 Five Prime Therapeutics Latest Developments

11.7 Credit Suisse Securities

11.7.1 Credit Suisse Securities Company Information

11.7.2 Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered

11.7.3 Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)

11.7.4 Credit Suisse Securities Main Business Overview

11.7.5 Credit Suisse Securities Latest Developments

11.8 Dana-Farber Cancer Institute

11.8.1 Dana-Farber Cancer Institute Company Information

11.8.2 Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered

11.8.3 Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)

11.8.4 Dana-Farber Cancer Institute Main Business Overview

11.8.5 Dana-Farber Cancer Institute Latest Developments

11.9 Deerfield Partners

11.9.1 Deerfield Partners Company Information

11.9.2 Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered

11.9.3 Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)

11.9.4 Deerfield Partners Main Business Overview

11.9.5 Deerfield Partners Latest Developments

11.10 Onyx Pharmaceuticals

11.10.1 Onyx Pharmaceuticals Company Information

11.10.2 Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered

11.10.3 Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)

11.10.4 Onyx Pharmaceuticals Main Business Overview

11.10.5 Onyx Pharmaceuticals Latest Developments

11.11 Juno Therapeutics

11.11.1 Juno Therapeutics Company Information

11.11.2 Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered

11.11.3 Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)

11.11.4 Juno Therapeutics Main Business Overview

11.11.5 Juno Therapeutics Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size CAGR by Region (2019 VS 2023 VS 2030) & (\$ Millions)
- Table 2. Major Players of Bispecific Antibodies
- Table 3. Major Players of Antibody Drug Conjugates
- Table 4. Major Players of Chimeric Antigen Receptor T-Cells
- Table 5. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size CAGR by Type (2019 VS 2023 VS 2030) & (\$ Millions)
- Table 6. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2019-2024) & (\$ Millions)
- Table 7. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Type (2019-2024)
- Table 8. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size CAGR by Application (2019 VS 2023 VS 2030) & (\$ Millions)
- Table 9. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2019-2024) & (\$ Millions)
- Table 10. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Application (2019-2024)
- Table 11. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Players (2019-2024) & (\$ Millions)
- Table 12. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Player (2019-2024)
- Table 13. B-Cell Maturation Antigen (BCMA) Targeted Therapies Key Players Head office and Products Offered
- Table 14. B-Cell Maturation Antigen (BCMA) Targeted Therapies Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
- Table 15. New Products and Potential Entrants
- Table 16. Mergers & Acquisitions, Expansion
- Table 17. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Regions 2019-2024 & (\$ Millions)
- Table 18. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Regions (2019-2024)
- Table 19. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Country/Region (2019-2024) & (\$ millions)
- Table 20. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Country/Region (2019-2024)

Table 21. Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024) & (\$ Millions)

Table 22. Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Country (2019-2024)

Table 23. Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2019-2024) & (\$ Millions)

Table 24. Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Type (2019-2024)

Table 25. Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2019-2024) & (\$ Millions)

Table 26. Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Application (2019-2024)

Table 27. APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2019-2024) & (\$ Millions)

Table 28. APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Region (2019-2024)

Table 29. APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2019-2024) & (\$ Millions)

Table 30. APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Type (2019-2024)

Table 31. APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2019-2024) & (\$ Millions)

Table 32. APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Application (2019-2024)

Table 33. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024) & (\$ Millions)

Table 34. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Country (2019-2024)

Table 35. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2019-2024) & (\$ Millions)

Table 36. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Type (2019-2024)

Table 37. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2019-2024) & (\$ Millions)

Table 38. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Application (2019-2024)

Table 39. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2019-2024) & (\$ Millions)

Table 40. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies

Market Size Market Share by Region (2019-2024)

Table 41. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2019-2024) & (\$ Millions)

Table 42. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Type (2019-2024)

Table 43. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2019-2024) & (\$ Millions)

Table 44. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Application (2019-2024)

Table 45. Key Market Drivers & Growth Opportunities of B-Cell Maturation Antigen (BCMA) Targeted Therapies

Table 46. Key Market Challenges & Risks of B-Cell Maturation Antigen (BCMA) Targeted Therapies

Table 47. Key Industry Trends of B-Cell Maturation Antigen (BCMA) Targeted Therapies

Table 48. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Forecast by Regions (2025-2030) & (\$ Millions)

Table 49. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share Forecast by Regions (2025-2030)

Table 50. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Forecast by Type (2025-2030) & (\$ Millions)

Table 51. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Forecast by Application (2025-2030) & (\$ Millions)

Table 52. Transposagen Biopharmaceuticals Details, Company Type, B-Cell Maturation Antigen (BCMA) Targeted Therapies Area Served and Its Competitors

Table 53. Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered

Table 54. Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 55. Transposagen Biopharmaceuticals Main Business

Table 56. Transposagen Biopharmaceuticals Latest Developments

Table 57. Sutro Biopharma Details, Company Type, B-Cell Maturation Antigen (BCMA) Targeted Therapies Area Served and Its Competitors

Table 58. Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered

Table 59. Sutro Biopharma Main Business

Table 60. Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 61. Sutro Biopharma Latest Developments

Table 62. Malin Corporation Details, Company Type, B-Cell Maturation Antigen (BCMA) Targeted Therapies Area Served and Its Competitors

Table 63. Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered

Table 64. Malin Corporation Main Business

Table 65. Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 66. Malin Corporation Latest Developments

Table 67. Eureka Therapeutics Details, Company Type, B-Cell Maturation Antigen (BCMA) Targeted Therapies Area Served and Its Competitors

Table 68. Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered

Table 69. Eureka Therapeutics Main Business

Table 70. Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 71. Eureka Therapeutics Latest Developments

Table 72. firstVentury Equity Details, Company Type, B-Cell Maturation Antigen (BCMA) Targeted Therapies Area Served and Its Competitors

Table 73. firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered

Table 74. firstVentury Equity Main Business

Table 75. firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 76. firstVentury Equity Latest Developments

Table 77. Five Prime Therapeutics Details, Company Type, B-Cell Maturation Antigen (BCMA) Targeted Therapies Area Served and Its Competitors

Table 78. Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered

Table 79. Five Prime Therapeutics Main Business

Table 80. Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 81. Five Prime Therapeutics Latest Developments

Table 82. Credit Suisse Securities Details, Company Type, B-Cell Maturation Antigen (BCMA) Targeted Therapies Area Served and Its Competitors

Table 83. Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered

Table 84. Credit Suisse Securities Main Business

Table 85. Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 86. Credit Suisse Securities Latest Developments
Table 87. Dana-Farber Cancer Institute Details, Company Type, B-Cell Maturation Antigen (BCMA) Targeted Therapies Area Served and Its Competitors
Table 88. Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered
Table 89. Dana-Farber Cancer Institute Main Business
Table 90. Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (\$ million), Gross Margin and Market Share (2019-2024)
Table 91. Dana-Farber Cancer Institute Latest Developments
Table 92. Deerfield Partners Details, Company Type, B-Cell Maturation Antigen (BCMA) Targeted Therapies Area Served and Its Competitors
Table 93. Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered
Table 94. Deerfield Partners Main Business
Table 95. Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (\$ million), Gross Margin and Market Share (2019-2024)
Table 96. Deerfield Partners Latest Developments
Table 97. Onyx Pharmaceuticals Details, Company Type, B-Cell Maturation Antigen (BCMA) Targeted Therapies Area Served and Its Competitors
Table 98. Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered
Table 99. Onyx Pharmaceuticals Main Business
Table 100. Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (\$ million), Gross Margin and Market Share (2019-2024)
Table 101. Onyx Pharmaceuticals Latest Developments
Table 102. Juno Therapeutics Details, Company Type, B-Cell Maturation Antigen (BCMA) Targeted Therapies Area Served and Its Competitors
Table 103. Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Offered
Table 104. Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (\$ million), Gross Margin and Market Share (2019-2024)
Table 105. Juno Therapeutics Main Business
Table 106. Juno Therapeutics Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate 2019-2030 (\$ Millions)

Figure 6. B-Cell Maturation Antigen (BCMA) Targeted Therapies Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Figure 7. B-Cell Maturation Antigen (BCMA) Targeted Therapies Sales Market Share by Country/Region (2023)

Figure 8. B-Cell Maturation Antigen (BCMA) Targeted Therapies Sales Market Share by Country/Region (2019, 2023 & 2030)

Figure 9. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Type in 2023

Figure 10. B-Cell Maturation Antigen (BCMA) Targeted Therapies in Liver Cancer

Figure 11. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Liver Cancer (2019-2024) & (\$ Millions)

Figure 12. B-Cell Maturation Antigen (BCMA) Targeted Therapies in Respiratory Cancer

Figure 13. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Respiratory Cancer (2019-2024) & (\$ Millions)

Figure 14. B-Cell Maturation Antigen (BCMA) Targeted Therapies in Brain Cancer

Figure 15. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Brain Cancer (2019-2024) & (\$ Millions)

Figure 16. B-Cell Maturation Antigen (BCMA) Targeted Therapies in Others

Figure 17. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Others (2019-2024) & (\$ Millions)

Figure 18. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Application in 2023

Figure 19. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Player in 2023

Figure 20. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Regions (2019-2024)

Figure 21. Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2019-2024 (\$ Millions)

Figure 22. APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2019-2024 (\$ Millions)

Figure 23. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2019-2024 (\$ Millions)

Figure 24. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2019-2024 (\$ Millions)

Figure 25. Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Value Market Share by Country in 2023

Figure 26. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 27. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 28. Mexico B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 29. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 30. APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Region in 2023

Figure 31. APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Type in 2023

Figure 32. APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Application in 2023

Figure 33. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 34. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 35. Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 36. Southeast Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 37. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 38. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 39. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Country in 2023

Figure 40. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Type (2019-2024)

Figure 41. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size

Market Share by Application (2019-2024)

Figure 42. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 43. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 44. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 45. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 46. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 47. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Region (2019-2024)

Figure 48. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Type (2019-2024)

Figure 49. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Market Share by Application (2019-2024)

Figure 50. Egypt B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 51. South Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 52. Israel B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 53. Turkey B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 54. GCC Country B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth 2019-2024 (\$ Millions)

Figure 55. Americas B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 56. APAC B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 57. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 58. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 59. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 60. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 61. Mexico B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 62. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 63. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 64. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 65. Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 66. Southeast Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 67. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 68. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 69. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 70. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 71. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 72. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 73. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 74. Spain B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 75. Egypt B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 76. South Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 77. Israel B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 78. Turkey B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 79. GCC Countries B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2025-2030 (\$ Millions)

Figure 80. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size

Market Share Forecast by Type (2025-2030)

Figure 81. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size

Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth (Status and Outlook) 2024-2030

Product link: <https://marketpublishers.com/r/G19253D4D500EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G19253D4D500EN.html>